Biotechnology company Bavarian Nordic expects to sign more contracts for its vaccine against monkeypox after "overwhelming" interest from governments around the world, its management told investors on Tuesday.
The Danish company, which produces the only vaccine approved in the United States and Canada against monkeypox, has become the focus of a global rush from governments around the world hoping to bolster their preparedness against the virus.
